Pathogenesis, immunity, pathology, and pathophysiology in rickettsial diseases

Rickettsial Diseases

Volumn , Issue , 2007, Pages 15-26

  Walker, David H ^a   Ismail, Nahed ^a   Olano, Juan P ^a   Valbuena, Gustavo ^a   McBride, Jere ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85050927887     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (51)

1. Ogata H, Audic S, Renesto-Audiffren P. Mechanisms of evolution in Rickettsia conorii and R. prowazekii. Science 2001; 293:2093-2098.
2. McLeod MP, Qin X, Karpathy SE, et al. Complete genome sequence of Rickettsia typhi and comparison with sequences of other rickettsiae. J Bacteriol 2004; 186:5842-5855.
3. Eremeeva ME, Dasch GA, Silverman DJ. Quantitative analyses of variations in the injury of endothelial cells elicited by 11 isolates of Rickettsia rickettsii. Clin Diagn Lab Immunol 2001; 8:788-795.
4. Eremeeva ME, Silverman DJ. Effects of the antioxidant α-lipoic acid on human umbilical vein endothelial cells infected with Rickettsia rickettsii. Infect Immun 1998; 66:2290-2299.
5. Santucci LA, Gutierrez PL, Silverman DJ. Rickettsia rickettsii induces superoxide radical and superoxide dismutase in human endothelial cells. Infect Immun 1992; 60:5113-5118.
6. Valbuena G, Feng HM, Walker DH. Mechanisms of immunity against rickettsiae: new perspectives and opportunities offered by unusual intracellular parasite. Microbes Infect 2002; 4:625-633.
7. Rydkina E, Sahni SK, Santucci LA, et al. Selective modulation of antioxidant enzyme activities in host tissues during Rickettsia conorii infection. Microb Pathog 2004; 36:293-301.
8. Valbuena G, Walker DH. Changes in the adherens junctions of human endothelial cells infected with spotted fever group rickettsiae. Virchows Arch 2005; 446:379-382.
9. Davidson MG, Breitschwerdt ED, Walker DH, et al. Vascular permeability and coagulation during Rickettsia rickettsii infection in dogs. Am J Vet Res 1990; 51:165-170.
10. Harrell GT, Aikawa JF. Pathogenesis of circulatory failure in Rocky Mountain spotted fever: alterations in the blood volume and the thiocyanate space at various stages of the disease. Arch Intern Med 1949; 83:331-347.
11. Li H, Walker DH. rOmpA is a critical protein for the adhesion of Rickettsia rickettsii to host cells. Microb Pathog 1998; 24:289-298.
12. Uchiyama T. Adherence to and invasion of Vero cells by recombinant Escherichia coli expressing the outer membrane protein rOmpB of Rickettsia japonica. Ann NY Acad Sci 2003; 990:585-590.
13. Martinez JJ, Seveau S, Veiga E, et al. Ku70, a component of DNA-dependent protein kinase, is a mammalian receptor for Rickettsia conorii. Cell 2005; 123:1013-1023.
14. Martinez JJ, Cossart P. Early signaling events involved in the entry of Rickettsia conorii into mammalian cells. Cell 2004; 117:5097-5106.
15. Whitworth T, Popov VL, Yu XJ, et al. Expression of the Rickettsia prowazekii pld or tlyC gene in Salmonella enterica serovar typhimurium mediates phagosomal escape. Infect Immun 2005; 73: 668-673.
16. Renesto P, Dehoux P, Gouin E, et al. Identification and characterization of a phospholipase D-superfamily gene in rickettsiae. J Infect Dis 2003; 188:1276-1283.
17. Heinzen RA, Grieshaber SS, Van Kirk LS, et al. Dynamics of actin-based movement of Rickettsia rickettsii in Vero cells. Infect Immun 1999; 67:4201-4207.
18. Teysseire N, Chiche-Portiche C, Raoult D. Intracellular movements of Rickettsia conorii and R. typhi based on actin polymerization. Res Microbiol 1992; 143:821-829.
19. Gouin E, Egile C, Dehoux P, et al. The RickA protein of Rickettsia conorii activates the Arp2/3 complex. Nature 2004; 427:457-461.
20. Jeng RL, Goley ED, D’Alessio, et al. A Rickettsia WASP-like protein activates the Arp2/3 complex and mediates actin-based motility. Cell Microbiol 2004; 6(8):761-769.
21. Billings AN, Feng HM, Olano JP, et al. Rickettsial infection in murine models activates an early anti-rickettsial effect mediated by NK cells and associated with production of gamma interferon. Am J Trop Med Hyg 2001; 65:52-56.
22. Kaplanski G, Teysseire N, Farnarier C, et al. IL-6 and IL-8 production from cultured human endothelial cells stimulated by infection with Rickettsia conorii via a cell-associated IL-1 alpha-dependent pathway. J Clin Invest 1995; 96:2839-2844.
23. Clifton DR, Rydkina E, Freeman RS, et al. NF-κB activation during Rickettsia rickettsii infection of endothelial cells involves the activation of catalytic IκB kinases IKKαand IKKβand phosphorylation-proteolysis of the inhibitor protein IκBα. Infect Immun 2005; 73:155-165.
24. Feng H-M, Popov VL, Walker DH. Depletion of gamma interferon and tumor necrosis factor alpha in mice with Rickettsia conorii-infected endothelium: impairment of rickettsicidal nitric oxide production resulting in fatal, overwhelming rickettsial disease. Infect Immun 1994; 62:1952-1960.
25. Walker DH, Olano JP, Feng H-M. Critical role of cytotoxic T lymphocytes in immune clearance of rickettsial infection. Infect Immun 2001; 69:1841-1846.
26. Walker DH, Popov VL, Crocquet-Valdes PA, et al. Cytokine-induced, nitric oxide-dependent, intracellular antirickettsial activity of mouse endothelial cells. Lab Invest 1997; 76:129-138.
27. Feng HM, Walker DH. Mechanisms of intracellular killing of Rickettsia conorii in infected human endothelial cells, hepatocytes, and macrophages. Infect Immun 2000; 68:6729-6736.
28. Walker DH, Staiti A, Mansueto S, et al. Frequent occurrence of hepatic lesions in boutonneuse fever. Acta Trop 1986; 43:175-181.
29. Valbuena G, Bradford W, Walker DH. Expression analysis of the T-cell-targeting chemokines CXCL9 and CXCL10 in mice and humans with endothelial infections caused by rickettsiae of the spotted fever group. Am J Pathol 2003; 163:1357-1369.
30. Valbuena G, Walker DH. Effect of blocking the CXCL9/10-CXCR3 chemokine system in the outcome of endothelial-target rickettsial infections. Am J Trop Med Hyg 2004; 71(4):393-399.
31. Valbuena G, Walker DH. Expression of CX3CL1 (fractalkine) in mice with endothelial-target rickettsial infection of the spotted-fever group. Virchows Arch 2004; 446:21-27.
32. Feng HM, Whitworth T, Olano JP, et al. Fc-dependent polyclonal antibodies and antibodies to outer membrane proteins A and B, but not to lipopolysaccharide, protect SCID mice against fatal Rickettsia conorii infection. Infect Immun 2003; 72:2222-2228.
33. Feng HM, Whitworth T, Popov V, et al. Effect of antibody on the rickettsia-host cell interaction. Infect Immun 2004; 22:3524-3530.
34. Walker DH, Popov VL, Feng HM. Establishment of a novel endothelial target mouse model of a typhus group rickettsiosis: evidence for critical roles for gamma interferon and CD8 T lymphocytes. Lab Invest 2000; 80:1361-1372.
35. Vitale G, Mansueto S, Gambino G, et al. The acute phase response in Sicilian patients with bouton-neuse fever admitted to hospitals in Palermo, 1992-1997. J Infect 2001; 42:33-39.
36. Sumner JW, Sims KG, Jones DC, et al. Protection of guinea pigs from experimental Rocky Mountain spotted fever by immunization with baculovirus-expressed Rickettsia rickettsii rOmpA protein. Vaccine 1995; 13:29.
37. Diaz CM, Feng HM, Crocquet-Valdes P, Walker DH. Identification of protective components of two major outer membrane proteins of spotted fever group rickettsiae. Am J Trop Med Hyg 2001; 65:371-378.
38. Valbuena G, Jordan JM, Walker DH. T cells mediate cross-protective immunity between spotted fever group rickettsiae and typhus group rickettsiae. J Infect Dis 2004; 190:1221-1227.
39. Herrero-Herrero JI, Walker DH, Ruiz-Beltran R. Immunohistochemical evaluation of the cellular immune response to Rickettsia conorii in taches noires. J Infect Dis 1987; 155:802-805.
40. Walker DH, Hawkins HK, Hudson P. Fulminant Rocky Mountain spotted fever: its pathologic characteristics associated with glucose-6-phosphate dehydrogenase deficiency. Arch Pathol Lab Med 1983; 107:121-125.
41. Walker DH, Mattern WD. Acute renal failure in Rocky Mountain spotted fever. Arch Intern Med 1980; 139:443-448.
42. Kaplowitz LG, Fischer JJ, Sparling PF. Rocky Mountain spotted fever: a clinical dilemma. In: Remington JS, Swartz MN, eds. Current Clinical Topics in Infectious Disease. Vol. 2. New York: McGraw-Hill, 1981:89-108.
43. Walker DH, Occhino C, Tringali GR, et al. Pathogenesis of rickettsial eschars: the tache noire of boutonneuse fever. Hum Pathol 1988; 19:1449-1454.
44. Kaplowitz LG, Robertson GL. Hyponatremia in Rocky Mountain spotted fever: role of antidiuretic hormone. Ann Intern Med 1983; 98:334-335.
45. Helmick CG, Bernard KW, D’Angelo LJ. Rocky Mountain spotted fever: clinical, laboratory, and epidemiological features of 262 cases. J Infect Dis 1984; 150:480-488.
46. Walker DH, Crawford CG, Cain BG. Rickettsial infection of the pulmonary microcirculation: the basis for interstitial pneumonitis in Rocky Mountain spotted fever. Hum Pathol 1980; 11:263-272.
47. Elghetany TM, Walker DH. Hemostatic changes in Rocky Mountain spotted fever and Mediterranean spotted fever. Am J Clin Pathol 1999; 112:159-168.
48. Rao AK, Schapira M, Clements ML, et al. A prospective study of platelets and plasma proteolytic systems during the early stages of Rocky Mountain spotted fever. N Engl J Med 1988; 318:1021-1028.
49. Schmaier AH, Srikanth S, Elghetany MT, et al. Hemostatic/fibrinolytic protein changes in C3H/HeN mice infected with Rickettsia conorii-a model for Rocky Mountain spotted fever. Thromb Haemost 2001; 86:871-879.
50. Walker DH, Fishbein DB. Epidemiology of rickettsial diseases. Eur J Epidemiol 1991; 7:237-245.
51. Holman RC, Paddock CD, Curns AT, et al. Analysis of risk factors for fatal Rocky Mountain spotted fever: evidence for superiority of tetracyclines for therapy. J Infect Dis 2001; 184:1437-1444.